(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Most type 2 diabetes injections for weight loss are glucagon-like peptide-1 (GLP-1) receptor agonists. These drugs mimic the ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Drugs that belong to the class of GLP-1 receptor agonists could cause muscle loss These drugs reduce appetite and are used ...

Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...

Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

glucagon-like peptide-1 (GLP-1) receptor agonist independently developed by the company, in adult overweight/obese patients in China were presented as an oral presentation at ObesityWeek®? 2024. The ...